Yumi Aoyama, Seiko Sugiyama, Chieko Katayama, Koji Kamiya
{"title":"免疫抑制治疗的自身免疫性大疱病患者巨细胞病毒再激活的危险因素","authors":"Yumi Aoyama, Seiko Sugiyama, Chieko Katayama, Koji Kamiya","doi":"10.1111/ajd.13528","DOIUrl":null,"url":null,"abstract":"1. Hofmann SC, Leandro MJ, Morris SD et al. Effects of rituximabbased B-cell depletion therapy on skin manifestations of lupus erythematosus Report of 17 cases and review of the literature. Lupus 2013; 22: 932–9. 2. Gr€ onhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: A population-based cohort of 1088 patients in Sweden. Br. J. Dermatol. 2011; 164: 1335–41. 3. Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA et al. Assessment of Response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018; 154: 1432–40. 4. McCarthy EM, Sutton E, Nesbit S et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology 2018; 57: 470–9. 5. Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield MEP. Responses to rituximab suggest B cellindependent inflammation in cutaneous systemic lupus erythematosus. 2015; 1–23. https://doi.org/10.1002/art.39085.","PeriodicalId":243138,"journal":{"name":"The Australasian journal of dermatology","volume":" ","pages":"e343-e344"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/ajd.13528","citationCount":"4","resultStr":"{\"title\":\"Risk factors for cytomegalovirus reactivation in autoimmune bullous disease patients on immunosuppressive therapy.\",\"authors\":\"Yumi Aoyama, Seiko Sugiyama, Chieko Katayama, Koji Kamiya\",\"doi\":\"10.1111/ajd.13528\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"1. Hofmann SC, Leandro MJ, Morris SD et al. Effects of rituximabbased B-cell depletion therapy on skin manifestations of lupus erythematosus Report of 17 cases and review of the literature. Lupus 2013; 22: 932–9. 2. Gr€ onhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: A population-based cohort of 1088 patients in Sweden. Br. J. Dermatol. 2011; 164: 1335–41. 3. Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA et al. Assessment of Response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018; 154: 1432–40. 4. McCarthy EM, Sutton E, Nesbit S et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology 2018; 57: 470–9. 5. Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield MEP. Responses to rituximab suggest B cellindependent inflammation in cutaneous systemic lupus erythematosus. 2015; 1–23. https://doi.org/10.1002/art.39085.\",\"PeriodicalId\":243138,\"journal\":{\"name\":\"The Australasian journal of dermatology\",\"volume\":\" \",\"pages\":\"e343-e344\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/ajd.13528\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Australasian journal of dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.13528\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Australasian journal of dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.13528","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Risk factors for cytomegalovirus reactivation in autoimmune bullous disease patients on immunosuppressive therapy.
1. Hofmann SC, Leandro MJ, Morris SD et al. Effects of rituximabbased B-cell depletion therapy on skin manifestations of lupus erythematosus Report of 17 cases and review of the literature. Lupus 2013; 22: 932–9. 2. Gr€ onhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: A population-based cohort of 1088 patients in Sweden. Br. J. Dermatol. 2011; 164: 1335–41. 3. Quelhas Da Costa R, Aguirre-Alastuey ME, Isenberg DA et al. Assessment of Response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018; 154: 1432–40. 4. McCarthy EM, Sutton E, Nesbit S et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology 2018; 57: 470–9. 5. Vital EM, Wittmann M, Edward S, Md Yusof MY, MacIver H, Pease CT, Goodfield MEP. Responses to rituximab suggest B cellindependent inflammation in cutaneous systemic lupus erythematosus. 2015; 1–23. https://doi.org/10.1002/art.39085.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
